Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep;15(1):19-23.
doi: 10.1097/CND.0b013e31829e22e3.

Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A

Nicholas E Johnson  1 , Chad R Heatwole, Michele Ferguson, Janet E Sowden, Shanie Jeanat, David N Herrmann
Affiliations

Patient identification of the symptomatic impact of charcot-marie-tooth disease type 1A

Nicholas E Johnson et al. J Clin Neuromuscul Dis. 2013 Sep.

Abstract

Objective: The burden of Charcot-Marie-Tooth type 1A (CMT1A), the most common inherited peripheral neuropathy, including impact on patient quality of life (QOL) is not well understood. This study aims to qualitatively describe the range of symptoms associated with CMT1A and impact on QOL.

Methods: We performed qualitative interviews with 16 adult CMT1A patients. Each interview was analyzed using a qualitative framework technique to identify and index symptoms by theme.

Results: Sixteen patients provided 656 quotes. One hundred forty-five symptoms of importance were identified representing 20 symptomatic themes. Symptoms associated with difficulty with mobility and ambulation, specific activity impairment, and emotional distress were the most frequently mentioned.

Conclusions: Multiple symptoms contribute to CMT1A disease burden, some previously underrecognized. Improved recognition of underrecognized symptoms will optimize patient care and QOL.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Charcot Marie Tooth Disease Type 1A Symptom Domain Model (A) and Quote Frequency (B).
See this image and copyright information in PMC

References

    1. Reilly MM, Shy ME. Diagnosis and new treatments in genetic neuropathies. J Neurol Neurosurg Psychiatry. 2009;80:1304–14. - PubMed
    1. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991;66:219–32. - PubMed
    1. Raeymaekers P, Timmerman V, Nelis E, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord. 1991;1:93–7. - PubMed
    1. Vinci P, Serrao M, Millul A, et al. Quality of life in patients with Charcot-Marie-Tooth disease. Neurology. 2005;65:922–4. - PubMed
    1. Padua L, Pareyson D, Aprile I, et al. Natural history of CMT1A including QoL: a 2-year prospective study. Neuromuscul Disord. 2008;18:199–203. - PubMed

Publication types